

FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ANALYSIS REPORT

Patient Name:	SAMPLE, JANET	Cytogenetics Number:	SK-XXXX
Date of Birth:	03/16/1984	Customer Specimen ID:	XXX-XXXXXX
Sex:	Female	Collection Date:	02/23/2016
Specimen Type:	FETAL TISSUE	Received Date:	02/23/2016
Physician:	JANE DOCTOR, M.D.	Requested Date:	03/09/2016
Clinical Data:	FETAL DEMISE	Reported Date:	03/10/2016

Results: **Abnormal FISH result for BCR (Cytocell)**

INTERPRETATION: Abnormal result for the POC Aneuploidy FISH panel. This pattern is consistent with a female with trisomy 22.

FISH ANALYSIS

Probe	Chromosome Target	Result
BCR (Cytocell)	TRISOMY 22	Positive
RB1 (Abbott)	TRISOMY 13	Negative
16qhet (Cytocell)	TRISOMY 16	Negative
D18Z1 (Abbott)	TRISOMY 18	Negative
D21S259 (Abbott)	TRISOMY 21	Negative
DXZ1 (Abbott)	SEX CHROMOSOME ANEUPLOIDY	Negative
DYZ3 (Abbott)	SEX CHROMOSOME ANEUPLOIDY	Negative

FISH INTERPRETATION


- Two signals for chromosome 22 were seen in 185 out of 200 (92.50%) interphase nuclei examined.**
- Two signals for chromosome 13 were seen in 195 out of 200 (97.50%) interphase nuclei examined.
- Two signals for chromosome 16 were seen in 194 out of 200 (97.00%) interphase nuclei examined.
- Two signals for chromosome 18 were seen in 198 out of 200 (99.00%) interphase nuclei examined.
- Two signals for chromosome 21 were seen in 199 out of 200 (99.50%) interphase nuclei examined.
- Two signals for chromosome X were seen in 195 out of 200 (97.50%) interphase nuclei examined.
- No signals for the Y chromosome were seen in 200 out of 200 (100.00%) interphase nuclei examined.

JANE DOCTOR, M.D.
SAMPLE HOSPITAL
1234 MEDICAL CENTER DRIVE
CITY, ST 00000



FLUORESCENCE IN SITU HYBRIDIZATION (FISH) ANALYSIS REPORT

Patient Name: SAMPLE, JANET	Cytogenetics Number: SK-XXXX
Date of Birth: 03/16/1984	Customer Specimen ID: XXX-XXXXXX



CPT Codes: 88377x3

A control subject processed simultaneously showed a normal signal pattern in all 40 interphase nuclei examined.

ISCN Diagnosis 13q14(RB1x2)[195/200], 16q11.2(16qhetx2)[194/200], 18p11.1-q11.1(D18Z1x2)[198/200],
21q22.13-q22.2(D21S259x2,D21S341x2,D21S342x2)[199/200], 22q11.22(BCRx2)[185/200],
Xp11.1-q11.1(DXZ1x2)[195/200], Yp11.1-q11.1(DYZ3x0)[200/200]

Note: The Aneuvysion Assay Kit has been cleared by the FDA for use in conjunction with fetal karyotype analysis that provides a rapid method for detection of trisomy 13, 18, 21 and sex chromosome aneuploidies. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. The 16qhet and BCR probes are special order probes designed and manufactured by the Cytocell myProbes service. The 16qhet probe is designed to hybridize to the heterochromatin region on chromosome 16 (16q11.2). The BCR probe is designed to hybridize to chromosome 22 within the bands q11.22-q11.23.

Reviewed By: _____

KATHLEEN LEPPIG, M.D.

JANE DOCTOR, M.D.
SAMPLE HOSPITAL
1234 MEDICAL CENTER DRIVE
CITY, ST 00000

